Patents by Inventor Jeffry Cutrera

Jeffry Cutrera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CARCINOMA HOMING PEPTIDE (CHP), ITS ANALOGS, AND METHODS OF USING
    Publication number: 20170260246
    Abstract: A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models. CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 14, 2017
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Shulin Li, Jeffry Cutrera, Xueqing Xia
  • Carcinoma homing peptide (CHP), its analogs, and methods of using
    Patent number: 9657077
    Abstract: A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 23, 2017
    Assignees: UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Shulin Li, Jeffry Cutrera, Xueqing Xia
  • Carcinoma Homing Peptide (CHP), Its Analogs, and Methods of Using
    Publication number: 20120208770
    Abstract: A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.
    Type: Application
    Filed: February 9, 2012
    Publication date: August 16, 2012
    Inventors: Shulin Li, Jeffry Cutrera, Xueqing Xia